Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin

被引:47
作者
Eap, CB
Guentert, TW
SchaublinLoidl, M
Stabl, M
Koeb, L
Powell, K
Baumann, P
机构
[1] DEPT UNIV PSYCHIAT ADULTE,UNITE BIOCHIM & PSYCHOPHARMACOL CLIN,PRILLY,SWITZERLAND
[2] HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND
关键词
D O I
10.1016/S0009-9236(96)80010-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Concentrations of total (R) + (S) and of the enantiomers (R) and (S) of thioridazine and metabolites were measured in 21 patients who were receiving 100 mg thioridazine for 14 days and who were comedicated with moclobemide (450 mg/day). Two patients were poor metabolizers of dextromethorphan and one was a poor metabolizer of mephenytoin. Cytochrome P450IID6 (CMP2D6) is involved in the formation of thioridazine 2-sulfoxide (2-SO) from thioridazine and also probably partially in the formation of thioridazine 5-sulfoxide (5-SO), but not in the formation of thioridazine 2-sulfone (2-SO,) from thioridazine 2-SO. Significant correlations between the mephenytoin enantiomeric ratio and concentrations of thioridazine and metabolites suggest that cytochrome P450IIC19 could contribute to the biotransformation of thioridazine into yet-unknown metabolites, other than thioridazine 2-SO, thioridazine 2-SO2, or thioridazine 5-SO. An enantioselectivity and a large interindividual variability in the metabolism of thioridazine have been shown: measured (R)/(S) ratios of thioridazine, thioridazine 2-SO fast eluting (FE), thioridazine 2-SO slow eluting (SE), thioridazine 2-SO (FE+SE), thioridazine 2-SO2, thioridazine 5-SO(FE), and thioridazine 5-SO(SE) were (mean a SD) 3.48 +/- 0.93 (range, 2.30 to 5.80), 0.45 +/- 0.22 (range, 0.21 to 1.20), 22.7 +/- 8.1 (range, 6.1 to 40.1), 4.64 +/- 0.68 (range, 2.85 to 5.70), 3.26 +/- 0.58 (range, 2.30 to 4.30), 0.049 +/- 0.019 (range, 0.021 to 0.087), and 67.2 +/- 66.2 (range, 16.8 to 248), respectively. CYP2D6 is apparently involved in the formation of (S)-thioridazine 2-SO(FE), (R)thioridazine 2-SO(SE), and also probably (S)-thioridazine 5-SO(FE) and (R)-thioridazine 5-SO(SE).
引用
收藏
页码:322 / 331
页数:10
相关论文
共 34 条
[1]   DEXTROMETHORPHAN AND MEPHENYTOIN PHENOTYPING OF PATIENTS TREATED WITH THIORIDAZINE OR AMITRIPTYLINE [J].
BAUMANN, P ;
MEYER, JW ;
AMEY, M ;
BAETTIG, D ;
BRYOIS, C ;
JONZIERPEREY, M ;
KOEB, L ;
MONNEY, C ;
WOGGON, B .
THERAPEUTIC DRUG MONITORING, 1992, 14 (01) :1-8
[2]   GC AND GC-MS PROCEDURES FOR SIMULTANEOUS PHENOTYPING WITH DEXTROMETHORPHAN AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M .
CLINICA CHIMICA ACTA, 1988, 171 (2-3) :211-222
[3]  
BAUMANN P, 1994, NEUROPSYCHOPHARMACOL, V10, pS75
[4]   REPORT ON THE WORKSHOP MOLECULAR-BASIS OF POLYMORPHIC DRUG OXIDATION IN MAN, OTZENHAUSEN, 1983 [J].
BREIMER, DD ;
DENGLER, HJ ;
EICHELBAUM, M ;
KALOW, W ;
MEYER, U ;
SMITH, RL ;
SJOQVIST, F ;
ULLRICH, V .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 27 (03) :253-257
[5]   ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].
BREYERPFAFF, U ;
PFANDL, B ;
NILL, K ;
NUSSER, E ;
MONNEY, C ;
JONZIERPEREY, M ;
BAETTIG, D ;
BAUMANN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358
[6]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[7]   QUINIDINE INHIBITS THE 2-HYDROXYLATION OF IMIPRAMINE AND DESIPRAMINE BUT NOT THE DEMETHYLATION OF IMIPRAMINE [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) :155-160
[8]   RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS [J].
BROSEN, K .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :220-239
[10]   DETERMINATION OF THE ENANTIOMERS OF THIORIDAZINE, THIORIDAZINE 2-SULFONE, AND OF THE ISOMERIC PAIRS OF THIORIDAZINE 2-SULFOXIDE AND THIORIDAZINE 5-SULFOXIDE IN HUMAN PLASMA [J].
EAP, CB ;
KOEB, L ;
POWELL, K ;
BAUMANN, P .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 669 (02) :271-279